15:14:45 EDT Mon 10 Aug 2026
Enter Symbol
or Name
USA
CA



BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

2026-08-10 09:05 ET - News Release

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

PR Newswire

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.

An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.


 Contacts:



 Investors                              
 Media



 
         Traci McCarty                        Marni Kottle



 
         BioMarin Pharmaceutical Inc.         BioMarin Pharmaceutical
                                                  Inc.



 
         (415) 455-7558                       (650) 374-2803

View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-at-the-canaccord-genuity-46th-annual-growth-conference-on-wednesday-august-12-2026-at-800am-et-in-boston-302844104.html

SOURCE BioMarin Pharmaceutical Inc.

© 2026 Canjex Publishing Ltd. All rights reserved.